ERBB2 and breast carcinoma: Upregulation of MALAT1 in breast cancer induces EMT and decreases trastuzumab sensitivity in HER2+ breast cancer, and the mechanism is associated with PI3/Akt-mediated FOXO1 nuclear retention.